Cargando…
421 A Phase 1 and Randomized Phase 2 Clinical Trial of Selinexor and Temozolomide in Recurrent Glioblastoma Among Adults: The Product of a Successful Team Science Approach
OBJECTIVES/GOALS: Selinexor is a novel XPO1 inhibitor that blocks nuclear export, thus impairing DNA repair and causing apoptosis. Our goal was to conduct preclinical and clinical studies to test our hypothesis that selinexor’s efficacy is boosted by priming with temozolomide and is associated with...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cambridge University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129817/ http://dx.doi.org/10.1017/cts.2023.454 |